A common phenotypic change in cancer is a dramatic transformation of cellular glycosylation. Functional studies of particular tumour-associated oligosaccharides are difficult to interpret conclusively, but carbohydrate-binding proteins are likely to contribute to progression of the tumour. This review discusses the potential role of CLRs (C-type lectin receptors), expressed by antigen-presenting cells of the immune system, in tumour recognition and immune modulation. Studies in recent years have provided significant insight into the immunomodulatory function of CLR during infections, but their role in cancer remains elusive; some strongly bind tumour cells and antigens, indicating participation in malignancy. The potential to use recombinant CLR as diagnostic tools will also be discussed.
Introduction
Glycosylation of proteins and lipids in mammalian cells is mediated by a large number of enzymes including glycosyltransferases that catalyse the transfer of a sugar from a donor molecule to a substrate, and glycosidases that catalyse the hydrolysis of glycosidic bonds. The expression of these enzymes is highly regulated according to cell metabolism, activation and microenvironmental changes. During malignant transformation of the cell this 'glycosylation machinery' is significantly affected, resulting in altered expression of glycan epitopes on the cell surface and secreted proteins [1] . As glycans play a major role in cell communication, adhesion and migration, these changes significantly affect tumour cell behaviour and survival. Certain glycan changes frequently occur and may be considered as 'tumour-specific', correlating with poor disease prognosis. Examples of these are the blood group-related antigens of the ABH and Lewis systems. ABH antigen expression is absent in the normal colon but significantly expressed on tumour cells [2] . Expression of the blood grouprelated Lewis y antigen is observed in adenocarcinoma and has been shown to correlate with poor prognosis in breast cancer [3] . Sialyl-Lewis A and sialyl-Lewis x carbohydrate antigens are significantly up-regulated in cancer and appear to promote tumour progression in colon carcinoma [4, 5] .
Altered glycan expression by transformed cells has long been studied using plant lectins and glycan-specific antibodies which have been useful for guiding disease diagnoses and enabling more accurate prognoses [6] . The lectins from Key words: cancer, carcinoembryonic antigen (CEA), C-type lectin, dendritic cell, glycosylation, mucin.
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Helix pomatia [HPA (Helix pomatia agglutinin)] and Ulex europaeus [UEA-I (Ulex europaeus agglutinin I)] have been used to assess breast cancer biopsy specimens and shown to be prognostic factors for patient survival [7, 8] . Another example is a lectin from Phaseolus vulgaris [PHA-L (leucocyte-agglutinating phytohaemagglutinin)] that recognizes branched N-glycans often highly exposed in cancer [due to overexpression of the glycosyltransferase GlcNAcT-V (N-acetylglucosaminyltransferase V)]. Staining of primary tumours with PHA-L is associated with metastasis and decreased survival in colorectal cancer [9] . These are just a few examples of the use of lectins for the detection of cancerspecific glycan changes in tumour biopsies.
Glycoproteins in cancer
Most of the widely used antibody-based cancer biomarker tests detect glycoproteins. The markers include CEA (carcinoembryonic antigen), a marker of colorectal cancer; CA-125 (cancer antigen 125; MUC16), frequently used to diagnose ovarian cancer; the epithelial mucin MUC1 (CA 15-3) a common marker for breast cancer; and PSA (prostatespecific antigen) [10] [11] [12] [13] . The serum levels of these proteins have been an invaluable indicator for tumour surveillance. However, many of these assays are not very specific and there is significant room for improvement. Antigen glycosylation may vary extensively depending on the disease status and this information affords the possibility of increasing diagnostic specificity and sensitivity.
MUC1 (CA 15-3) is a membrane-bound glycoprotein that is expressed on the apical surface of glandular epithelial cells [14] . On the other hand, deregulated expression of MUC1 is a prominent characteristic of cancer where it is frequently overexpressed and aberrantly glycosylated. MUC1 is overexpressed in >90 % of breast carcinomas and frequently in other types of cancer, including ovarian, colon, pancreatic and lung carcinomas [15] . Structurally, MUC1 consists of a large extracellular subunit composed of several (∼20-120) 20-amino-acid tandem repeats and a smaller subunit composed of a small extracellular domain, a transmembrane domain and a cytoplasmic tail. The intracellular tail of MUC1 is known to interact with signalling molecules, which are thought to be responsible for tumorigenic effects. Within each tandem repeat there are five potential O-glycosylation sites (serine or threonine amino acids) [16] . Glycosylation of these sites with complex oligosaccharides is crucial to the mucin structure and function. These oligosaccharides are involved in specific ligand-receptor interactions where the tandem repeats provide a high degree of multivalency. Compared with O-glycans of normal mucins, cancer associated O-glycans can be highly sialylated and they are often truncated. In breast cancer, expression of Tn-(GalNAcα) and ThomsenFriedenreich antigens (TF; core 1; Galβ1-3GalNAcα), including their sialylated counterparts, is common [17] . Normally, core 2 (Galβ1-3[GlcNAcβ1-6]GalNAcα) Olinked structures prevail on normal breast epithelia, but core 3 (GlcNAcβ1-3GalNAcα) in the normal colon [17] . In cancer, these glycan structures are often replaced by core 1, indicating that core 1 structures play an important role in cancer progression.
CEA is a 180-kDa glycoprotein of the Ig supergene family. The CEA molecule is GPI (glycosylphosphatidylinositol)-anchored in the plasma membrane and contains a large number of N-glycosylation sites within the extracellular Ig domains [18] . The primary role of CEA, and other CEA family members, is intercellular adhesion [19] . CEA is normally expressed during oncofetal development and is expressed in cells within normal colonic mucosa. It is overexpressed in nearly all colorectal cancers, as well as other epithelial cancers such as ovarian, bladder and breast cancers. Interestingly, CEA markedly inhibits the apoptosis of cells when deprived of their anchorage to the extracellular matrix, a process known as anoikis [20] . This may be a process supporting metastasis of the tumour cells. Clinically, CEA is widely used as a marker of tumour progression. Elevated CEA in serum is associated with a larger tumour burden, and a poorer prognosis presurgically, and may indicate a recurrence of disease post-surgically [21, 22] .
Not surprisingly, CEA glycosylation changes during cellular transformation. CEA on colorectal cancer cells that have metastasized to the liver is highly fucosylated, including Lewis x and Lewis y carbohydrate structures [23, 24] . There has been significant interest in the pathophysiological role of glycosylation in cancer, especially since correlations have been observed between certain glycosylation patterns and clinical outcome. How would surface glycans affect tumour cell progression? The cellsurface glycoproteins are either adhesion or anti-adhesion molecules, contributing to the complex array of intercellular interactions. Secreted glycoproteins, such as MUC1 and CEA, often mirror the same glycosylation changes as those seen on the cell surface and these soluble antigens could interact with distant cells to influence tumour progression [25] . To mediate functional interactions, glycosylated tumour antigen should interact with glycan-binding proteins (lectins) at the cell surface. In this review, we focus on interactions of glycosylated tumour antigens with the membrane-bound CLRs (C-type lectin receptors), primarily expressed on APCs (antigen-presenting cells) of the immune system.
DCs (dendritic cells) in cancer
DCs are professional APCs that are seeded throughout peripheral tissues, sampling their environment for foreign antigens. Immature DCs are capable of recognizing selfand non-self-antigens and processing them for antigen presentation. They are derived from precursor DCs, generated in the bone marrow, and can be detected in almost all tissues. After antigen uptake, the DC migrates to the draining lymph node where it presents antigenic peptides to naive T-cells in the context of MHC molecules. This continuously occurs in the steady state where the DC presents self-and innocuous environmental antigens. The immature DC is not capable of inducing an inflammatory immune response, thereby sustaining immunological tolerance to non-harmful antigens. In contrast, antigens derived from pathogens trigger PRRs (pattern-recognition receptors) such as TLRs (Toll-like receptors) and induce maturation of the DC. Mature DCs are efficient inducers of T-cell immunity and they include signals that direct the type of T-cell responses. Thus DCs are crucial players in steering adaptive immune responses, determining the direction of the T-cell response [26] .
The recognition and uptake of antigens by DCs is the first stage towards induction of the adaptive immune response. The DCs express a broad range of antigen receptors that allow them to bind and take up antigens for presentation [26] . These include the CLR that recognize glycan structures on proteins and lipids [27] . The CLR interact with carbohydrates in a calcium-dependent manner via their CRD (carbohydrate recognition domain) and are grouped according to an amino acid motif involved in glycan recognition and calcium ion co-ordination [28] . The galactose-specific CLR contain a QPD amino acid motif and recognize terminal N-acetylgalactosamine (GalNAc) or galactose. In contrast, mannose-specific CLRs contain the EPN amino acid motif that allows them to recognize mannose-and/or fucose-terminated glycans [28] . CLRs such as DC-SIGN (DC-specific intracellular adhesion molecule-3 grabbing non-integrin) and MGL (macrophage galactose-type C-type lectin) are expressed on APCs and represent the mannose/fucose and GalNAc-specific CLRs, respectively. Interestingly, both these CLRs not only primarily bind a number of pathogens, but also exhibit specificity for endogenous antigens and tumour-associated glycan structures [29] [30] [31] . First, several colon and breast cancer cell lines are recognized by DC-SIGN and MGL, offering one mechanism for immature DC to communicate with tumour cells. Secondly, these CLR recognize soluble tumour antigens that present glycan structures generated by the tumour. DC-SIGN binds Lewis structures presented on cancer-associated CEA in colon carcinoma [29] and MGL recognizes GalNAc on tumour-associated MUC1 [32, 33] .
Recognition by CLRs leads to the internalization of the antigen, processing and presentation. The underlying signalling processes are complex and depend on the DC subset, the cross-talk with other PRRs and the ligand-specific signalling pathway [34] . Certain CLRs are associated with ITAM (immunoreceptor tyrosine-based activation motif)-containing adaptor molecules such as the Fc receptor γ chain or DAP12 (DNAX-activating protein of 12 kDa) [34] . Other CLRs, such as DC-SIGN, induce signalling pathways through the activation of protein kinases or phosphatases that either directly or indirectly interact with their cytoplasmic domains. DC-SIGN is also a receptor that modulates TLRinduced gene expression [35] . Interestingly, DC-SIGN has not been shown to signal on its own but the cross-talk of DC-SIGN with NF-κB (nuclear factor κB)-inducing TLRs, such as TLR3 and TLR4, results in modulation of the TLRinduced signalling and the immune response [35] .
It is interesting to speculate how DC-SIGN and MGL would regulate T-cell responses to tumours. Uptake of glycosylated tumour antigens via DC-SIGN results in antigen presentation to CD4
+ T-cells and cross-presentation to CD8
+ T-cells [36, 37] . Importantly, the microenvironment in which the DC resides at the moment of antigen processing determines the signals it will provide the tumour-specific Tcells. There is clinical evidence that DCs can mature in the intratumoral environment and the presence of mature DCs correlates with improved disease prognosis [38, 39] . Density of mature DC-LAMP + DCs was found to inversely correlate with tumour thickness in melanoma and poor prognosis [38] , and the presence of CD83 + DCs in breast cancer strongly correlated with increased survival [39] . Conversely, impaired immune surveillance may arise from altering DC maturation in concert with immune-suppressive factors associated with the tumour microenvironment [40] . Stat3 (signal transducer and activator of transcription 3) hyperactivation is highly prevalent in cancer and Stat3-mediated suppressive effects on DC function include regulation of soluble tumour-derived factors such as VEGF (vascular endothelial growth factor) and IL-10 (interleukin-10) [41] . Uptake of tumour antigens by CLR in the immunosuppressive environment may result in antigen-specific T-cell tolerance. Whether triggering of DC-SIGN, in cross-talk with other PRRs, influences DC maturation remains to be determined.
The CLR MGL is specific for end-standing GalNAc that naturally occur on glycoproteins and glycosphingolipids. Specific glycans containing terminal GalNAc moieties, expressed by the human helminth parasite Schistosoma mansoni, the gangliosides GM2 and GD2 and the tumour antigen MUC1 were identified as ligands for MGL [30, 32] . Binding to MUC1 isolated from tumour samples of colon carcinoma patients correlated with HPA binding, a lectin specific for GalNAc [32] . Human MGL has two murine MGL orthologues, mMGL1 and mMGL2. In the mouse, mMGL2 recognizes GalNAc and galactose and binds to different murine adenocarcinoma cell lines [42, 43] . mMGL2 can also be targeted to enhance antigen presentation to tumour-associated antigens [44] . Collectively, this indicates that MGL is a receptor for tumour-associated glycans, contributing to tumour immune responses. In contrast with DC-SIGN, very little is known about MGL signalling or MGL cross-talk with other receptors on DCs. Interestingly, MGL is up-regulated on tolerogenic DCs generated in the presence of glucocorticoids in vitro [45] and can be detected in synovial biopsies of rheumatoid arthritis patients, suggesting that MGL plays a role in immune modulation. Similar to DC-SIGN, MGL is expressed within colon tumours [29, 32] where it may contribute to tolerance to glycosylated antigens.
Currently, there are no data on the role of CLRs in tumour immunity in vivo. The function of particular oligosaccharides in the biology of cancer is very difficult to address, due to cellular heterogeneity within tumours. Moreover, microheterogeneity of glycosylation presents an additional problem [25] . Several studies have addressed the potential function of certain overexpressed glycans in vivo, but none have demonstrated a direct involvement of CLR on APCs. Expanding interest in tumour glycosylation during the past few years and advancements in molecular and biochemical techniques will provide insight into this mechanism.
CLR as diagnostic tools
Current methods of studying glycans, such as enzymatic removal of glycans followed by chromatography or MS, provide detailed information about glycans, but are not suitable for routine diagnostic analysis. In contrast, indirect methods to study glycan structures may be valuable, such as the use of lectin binding. Plant lectins have been an excellent tool to study glycosylation changes in cancer. This holds true for several methods such as the detection of blots of separated glycoproteins [46] and in ELISA-based systems [47] [48] [49] . Although plant lectins are quite specific for particular glycan structures, there are several variables that influence ligand binding. Lectins are influenced by glycan density and spacing, and their oligomerization contributes to ligand interactions [50] . This means that the lectin ELISA gives a rough, overall view of carbohydrate structures on the particular antigen. The advantage of the ELISA system is that it is easy to perform, requiring only standard laboratory equipment, and a large number of samples can be screened in one test. For routine-based diagnostic screening it is not necessary to elucidate the exact glycan structure of a tumour antigen. However, a relevant addition to a lectin ELISA would be to include recombinant human lectins, such as CLR, that recognize tumour-associated carbohydrate structures.
We have generated recombinant MGL and DC-SIGN fused with the Fc portion of human IgG antibodies and developed a novel ELISA to detect lectin binding to CEA and MUC1 from colon tissues (Figure 1 ). Lectin interaction was found to be antigen specific with low background signals. Comparing normal tissue lysates with tumour lysates, a consistent increase in CEA and MUC1 protein levels was noted. Conversely, consistent but high variation in lectin binding to the tumour antigens was observed between individual patient samples (E. Saeland, A. Belo, I. van Die, G. Meijer and Y. van Kook, unpublished work). These 'glycan signatures' provide information on the structure of relevant tumour antigens and how certain APC-uptake receptors bind them. Whether these diagnostic parameters correlate with tumour progression and disease prognosis remains to be determined.
Conclusions
CLRs on APCs play an important role for antigen uptake, presentation and immune modulation. Their contribution to tumour progression still remains to be established, although evidence indicates that CLRs mediate contact between APC and the tumour. This probably promotes antigen uptake and presentation, but surely may modulate DC function and, consequently, the T-cell repertoire. Similar to other lectins, recombinant CLR may be used as diagnostic indicators in lectin assays, which can contribute significantly to tumour diagnosis. 
